| DC10487 |
KO947
Featured
|
KO-947 is a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2), as a potential treatment for cancers in which the mitogen activated protein kinase (MAPK) pathway. |
|
| DC9788 |
KP1019(FFC14A) |
KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials. |
|
| DC7067 |
KPT-330(Selinexor)
Featured
|
KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor. |
|
| DC10454 |
KRN633
Featured
|
KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells. |
|
| DC8522 |
KW-2449
Featured
|
KW 2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase. |
|
| DC7449 |
KW-2478
Featured
|
KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM. Phase 1/2 |
|
| DC8023 |
KX2-391
Featured
|
KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. |
|
| DCAPI1512 |
Lapatinib
Featured
|
Lapatinib |
|
| DC3143 |
Lapatinib ditosylate
Featured
|
Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
|
| DC9433 |
Lapatinib (ditosylate) |
Lapatinib ditosylate(GW-572016 ditosylate) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
|
|
| DC11900 |
Lazertinib
Featured
|
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations |
|
| DC7801 |
LB-100
Featured
|
LB-100 is a small-molecular protein phosphatase 2A(PP2A)inhibitor with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells. |
|
| DC7186 |
LGK-974
Featured
|
LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM. |
|
| DC10099 |
BGB283 |
Lifirafenib（BGB-283） is a Novel potent and selective RAF Kinase and EGFR inhibitor. |
|
| DC9837 |
Larotrectinib (LOXO-101 sulfate)
Featured
|
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
|
| DC11448 |
LOXO 195(Selitrectinib)
Featured
|
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively. |
|
| DC8541 |
ORY-1001(Ladademstat)
Featured
|
ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
|
| DC10755 |
LSZ-102
Featured
|
LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. |
|
| DC10987 |
LTX-315 |
This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
|
| DC7456 |
LX1606 Hippurate
Featured
|
LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. |
|
| DC10828 |
LXH254
Featured
|
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
|
| DC6306 |
LY2157299(Galunisertib)
Featured
|
LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2. |
|
| DC8630 |
Ralimetinib 2MsOH(LY2228820)
Featured
|
LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
|
| DC10782 |
LY2510924
Featured
|
LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. |
|
| DC7943 |
LYS6K2(LY2584702) tosylate salt
Featured
|
LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
|
| DC7103 |
LY2603618(IC-83)
Featured
|
LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials. |
|
| DC7993 |
Prexasertib (LY2606368) 2HCl
Featured
|
LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC10796 |
Prexasertib (LY2606368)
Featured
|
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC7665 |
Gandotinib(LY2784544)
Featured
|
LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
|
| DC7019 |
LY-2874455
Featured
|
LY2874455 is a novel and potent FGF/FGFR inhibitor. |
|
